13-valent Pneumococcal Polysaccharide Conjugate Vaccine - Walvax Biotechnology
Alternative Names: 13-Valent pneumococcal conjugate vaccine - Walvax Biotechnology; PCV13-TT; WEUPHORIALatest Information Update: 27 Dec 2023
Price :
$50 *
At a glance
- Originator Walvax Biotechnology
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
Most Recent Events
- 23 Nov 2023 Phase-III clinical trials in Pneumococcal infections (Prevention, In infants) in Indonesia (IM) (NCT05934890)
- 07 Jul 2023 Walvax Biotechnology plans a phase-III trial for Pneumococcal infections (In infants, Prevention) in Indonesia (NCT05934890)
- 16 Oct 2020 Walvax Biotechnology completes a phase III trial in Pneumococcal infections (Prevention, In infants, In children) in China (Parenteral) in December 2017 (NCT02736240)